Xeltis, a company out of Zurich, Switzerland, has been granted FDA Humanitarian Use Device designation for the first available bioabsorbable cardiac pulmonary valve. It’s intended for fixing the right ventricular outflow tract in children with the congenital obstruction.
The device is made of a complex matrix composed of electrospun bioabsorbable polymers that are porous and allow for collagen and blood vessels to pervade and form new native tissue. In the meantime, as the healing process is occurring, the valve itself slowly breaks up and is taken over completely by the patient’s own tissue, hopefully resulting in a fully natural tract that’s just the right size and shape for the patient.
Here’s more about the company’s technology: